Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers from across the Medical Sciences Division are working hard to combat the COVID-19 crises. With particular strengths in infectious diseases and international health, we are well placed to contribute to better understanding and effectively controlling the epidemic. We have a long history of responding to crises, in the UK and around the world and are leaders in emergency vaccine development. During the 2014 Ebola outbreak, our scientists performed the world’s first human Ebola vaccine studies, starting them before any other university or company. Our researchers, in collaboration with partners across the globe, are working to develop an effective vaccine and drugs to target this virus, and have already introduced innovative public health measures and collaborative online tools that are being used in hospitals here and abroad.

Coronavirus-related news from across the Medical Sciences Division

Hidden damage to lungs from COVID-19 revealed in new research study from University of Oxford & Sheffield

Early findings from a study into longer-term damage amongst patients recovering from COVID-19 suggest that the use of cutting-edge scanning techniques may detect previously unseen lung damage.

Inhaled corticosteroids to be investigated as a possible treatment for Covid-19 in national PRINCIPLE Trial

In Covid-19, inhaled budesonide may prevent damaging inflammation, stop the virus from getting into lung cells and inhibit viral replication.

Oxford vaccine team shortlisted for parliamentary awards

The University of Oxford team who have developed a COVID-19 vaccine in record time have been shortlisted for the Excellence in Healthcare Award at the NHS Parliamentary Awards.

Oxford University breakthrough on global COVID-19 vaccine

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.

People in prison should be prioritised for any COVID-19 vaccine

Preventing serious complications from COVID-19 in potentially vulnerable populations in high risk environments, such as prisons, and preventing spread to surrounding communities needs a coordinated evidence-based approach to managing outbreaks of COVID-19 in prison settings.

Prior COVID-19 infection offers protection from re-infection for at least six months

A new study suggests that individuals who have previously had COVID-19 are highly unlikely to contract the illness again, for at least six months following their first infection.

Viruses shown to evolve as a result of different immune responses in different ethnic populations

New research into the HIV-1 virus has shed light on an important factor in the evolution of viruses, which is likely also to affect SARS-CoV-2 (the virus which causes COVID-19). This new insight could have important implications for vaccine development.

Oxford coronavirus vaccine produces strong immune response in older adults

The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.

Return to school sees improvement in children's mental health

Mental health difficulties in children increased during the first national lockdown (between March and June 2020), but have decreased since.

Interferon-b trial shows positive results

A trial of a new inhaled antiviral drug for COVID-19 has shown positive results and the drug is now moving into a larger international phase 3 trial of hospitalised patients.